Incyte Corporation vs Logitech International SA — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Logitech International SA trades at $101.7 (market cap $14.65B). The key difference: Incyte Corporation is the larger of the two by market cap, and Logitech International SA pays a 1.67% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | LOGI | |
|---|---|---|
Market Cap | $23.11B | $14.65B |
Sector | Health | Technology |
52-Week High | $118.52 | $126.69 |
52-Week Low | $67.38 | $85.84 |
Enterprise Value | $19.13B | $13.00B |
Dividend Yield | — | 1.67% |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →